Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 9, 2012, Pages 1377-1384

  Guarino, Elisa ^a   Nigi, Laura ^a   Patti, Aurora ^a,b   Fondelli, Cecilia ^a   Dotta, Francesco ^a,b  

^a UNIVERSITY OF SIENA   (Italy)

^b Fondazione Umberto di Mario ONLUS ^*  (Italy)

Author keywords

Dipeptidyl peptidase 4 (DPP 4) inhibitors; Metformin; Type 2 diabetes treatment; Vildagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLICLAZIDE; GLICLAZIDE PLUS METFORMIN; GLIMEPIRIDE PLUS METFORMIN; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS VILDAGLIPTIN; PLACEBO; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; TABLET; TREATMENT OUTCOME;

ADAMANTANE; ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; METFORMIN; NITRILES; PYRROLIDINES; TABLETS; TREATMENT OUTCOME;

EID: 84861394918     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.667078     Document Type: Review

References (46)

1. Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010;88(2):125-31
2. Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 2008;4(2):383-94
3. Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010;123(3 Suppl):S19-27
4. Miller RA, Birnbaum MJ. An energetic tale of AMPK-independent effects of metformin. J Clin Invest 2010;120(7):2267-70
5. Boyle JG, Salt IP, McKay GA. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. Diabet Med 2010;27(10):1097-106
6. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50(2):81-98
7. Correia S, Carvalho C, Santos MS, et al. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev Med Chem 2008;8(13):1343-54
8. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108(8):1167-74
9. Strack T. Metformin: a review. Drugs Today (Barc) 2008;44(4):303-14
10. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010(4):CD002967
11. He YL, Sabo R, Picard F, et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009;25(5):1265-72
12. Shomali M. Add-on therapies to metformin for type 2 diabetes. Expert Opin Pharmacother 2011;12(1):47-62
13. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52(1):17-30
14. Ahren B, Schweizer A, Dejager S, et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011;13(9):775-83
15. Seino Y. Understanding the incretin effect. J Clin Endocrinol Metab 2011;96(4):934-5
16. Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther 2011;33(5):528-76
17. Lotfy M, Singh J, Kalasz H, et al. Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus. Open Med Chem J 2011;5(Suppl 2):82-92
18. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71(11):1441-67
19. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-h acute glucose fluctuations. J Diabetes Complications 2010;24(2):79-83
20. Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials. Diabetes Obes Metab 2010;12(6):495-509
21. Schweizer A, Dejager S, Foley JE, et al. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population 75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011;13(1):55-64
22. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30(5):463-84
23. Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011;13(3):193-203
24. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24(3):489-94
25. Lindsay JR, Duffy NA, McKillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 2005;22(5):654-7
26. Hinke SA, Kuhn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002;291(5):1302-8
27. Dunning BE, Ligueros-Saylan M, D'Alessio DA, et al. Differential effect of DPP-4 inhibition on incretin hormone levels in drug-naive and metformin-treated patients with type 2 diabetes. Diabetologia 2006;49(Suppl 1):110-11
28. Migoya EM, Bergeron R, Miller JL, et al. Dipeptididyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88(6):801-8
29. Jeon HJ, Oh TK. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J 2011;35(5):529-35
30. Tahrani AA, Piya MK, Barnett AH. Drug evaluation: vildagliptin- metforminsingle-tablet combination. Adv Ther 2009;26(2):138-54
31. Novartis. Eucreas. Summary of Product Characteristics (UK). Available from: emc.medicines.org.uk/medicine/20735/ SPC/Eucreas+50+mg+850+mg+and+50 +mg+1000+mg+film-coated+tablets/ [Accessed February 2009]
32. Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27(12):2874-80
33. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related betacell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28(8):1936-40
34. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30(4):890-5
35. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41(5):368-73
36. Meier JJ, Vollmer M, Pennartz C, et al. Efficacy and safety of early combination of vildagliptin and metformin in comparison to placebo in patients with type 2 diabetes. Diabetologia 2009;52(Suppl 1):304
37. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11(5):506-15
38. Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes 2010;1(1):19-26
39. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11(2):157-66
40. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12(9):780-9
41. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010;27(3):318-26
42. Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial-a primary care, type 2 diabetes study. Diabetes Obes Metab 2009;11(10):978-86
43. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10(1):82-90
44. Bolli G, Dotta F, Colin L, et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009;11(6):589-95
45. He YL, Flannery B, Campestrini J, et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/ 1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 2008;24(6):1703-9
46. Halimi S, Schweizer A, Minic B, et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008;4(3):481-92